Bristol-Myers Squibb (NYSE: BMY) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $55.00 price target on the stock, down previously from $75.00.
LowReport
Bristol-Myers Squibb (NYSE: BMY) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $55.00 price target on the stock, down previously from $75.00.
Malignant Pleural Mesothelioma Market Report 2024-2030 with Analyst Recommendations - Expanding Clinical Trials for Novel RoA, Capitalizing on Emerging Markets in Asia-Pacific and Latin America [Yahoo! Finance]
LowReport
Malignant Pleural Mesothelioma Market Report 2024-2030 with Analyst Recommendations - Expanding Clinical Trials for Novel RoA, Capitalizing on Emerging Markets in Asia-Pacific and Latin America [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: